Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Rivet, Pierre
530  Ergebnisse:
OpenAccess-Volltexte X
Personensuche X
?
1

MEOX2 Transcription Factor Is Involved in Survival and Adhe..:

Tachon, Gaëlle ; Masliantsev, Konstantin ; Rivet, Pierre...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672280/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
2

MEOX2 Transcription Factor Is Involved in Survival and Adhe..:

Tachon, Gaëlle ; Masliantsev, Konstantin ; Rivet, Pierre...
info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers13235943.  , 2021
Link: https://hal.science/hal-..
 
?
3

MEOX2 Transcription Factor Is Involved in Survival and Adhe..:

Tachon, Gaëlle ; Masliantsev, Konstantin ; Rivet, Pierre...
info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers13235943.  , 2021
Link: https://hal.science/hal-..
 
?
4

MEOX2 Transcription Factor Is Involved in Survival and Adhe..:

Tachon, Gaëlle ; Masliantsev, Konstantin ; Rivet, Pierre...
info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers13235943.  , 2021
Link: https://hal.science/hal-..
 
?
5

Cell Cycle Changes after Glioblastoma Stem Cell Irradiation..:

Tachon, Gaelle ; Cortes, Ulrich ; Guichet, Pierre-Olivier...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213228/.  , 2018
Link: http://www.ncbi.nlm.nih...
 
?
6

Crizotinib targets in glioblastoma stem cells:

Junca, Audelaure ; Villalva, Claire ; Tachon, Gaëlle...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673924/.  , 2017
Link: http://www.ncbi.nlm.nih...
 
?
7

Clinical validation of the CE-IVD marked Therascreen MGMT k..:

Quillien, Véronique ; Lavenu, Audrey ; Ducray, François...
info:eu-repo/semantics/altIdentifier/doi/10.3233/CBM-170191.  , 2017
Link: https://univ-rennes.hal...
 
?
8

Clinical validation of the CE-IVD marked Therascreen MGMT k..:

Quillien, Véronique ; Lavenu, Audrey ; Ducray, François...
info:eu-repo/semantics/altIdentifier/doi/10.3233/CBM-170191.  , 2017
Link: https://univ-rennes.hal...
 
?
9

Clinical validation of the CE-IVD marked Therascreen MGMT k..:

Quillien, Véronique ; Lavenu, Audrey ; Ducray, François...
info:eu-repo/semantics/altIdentifier/doi/10.3233/CBM-170191.  , 2017
Link: https://univ-rennes.hal...
 
?
10

Clinical validation of the CE-IVD marked Therascreen MGMT k..:

Quillien, Véronique ; Lavenu, Audrey ; Ducray, François...
info:eu-repo/semantics/altIdentifier/doi/10.3233/CBM-170191.  , 2017
Link: https://univ-rennes.hal...
 
?
11

Clinical validation of the CE-IVD marked Therascreen MGMT k..:

Quillien, Véronique ; Lavenu, Audrey ; Ducray, François...
info:eu-repo/semantics/altIdentifier/doi/10.3233/CBM-170191.  , 2017
Link: https://univ-rennes.hal...
 
?
12

Clinical validation of the CE-IVD marked Therascreen MGMT k..:

Quillien, Véronique ; Lavenu, Audrey ; Ducray, François...
info:eu-repo/semantics/altIdentifier/doi/10.3233/CBM-170191.  , 2017
Link: https://univ-rennes.hal...
 
?
13

Clinical validation of the CE-IVD marked Therascreen MGMT k..:

Quillien, Véronique ; Lavenu, Audrey ; Ducray, François...
info:eu-repo/semantics/altIdentifier/doi/10.3233/CBM-170191.  , 2017
Link: https://univ-rennes.hal...
 
?
14

Clinical validation of the CE-IVD marked Therascreen MGMT k..:

Quillien, Véronique ; Lavenu, Audrey ; Ducray, François...
info:eu-repo/semantics/altIdentifier/doi/10.3233/CBM-170191.  , 2017
Link: https://hal-univ-rennes1..
 
?
15

Clinical validation of the CE-IVD marked Therascreen MGMT k..:

Quillien, Véronique ; Lavenu, Audrey ; Ducray, François...
info:eu-repo/semantics/altIdentifier/doi/10.3233/CBM-170191.  , 2017
Link: https://univ-rennes.hal...
 
1-15